Professor | Honglei Chen | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Honglei Chen
Contact Information	hl-chen@whu.edu.cn
Language ability	English, Chinese
Province	Hubei

Upload Avatar (500 x 500)

Name

Honglei Chen

Contact Information

hl-chen@whu.edu.cn

Language ability

English, Chinese

Province

Hubei

University/Lab Affiliation and Title	Wuhan University
Faculty	Basic Medical Sciences
Academic Background & Achievements	2012.5-2013.8 Postdoctoral Fellow, Department of Biochemistry, Rush University Medical Center, USA 2005.9-2010.6 PhD in Internal Medicine, Renmin Hospital of Wuhan University 1999.9-2002.7 Master in Pathology and Pathophysiology, Basic Medical College of Wuhan University 1994.9-1999.7 Bachelor in Clinical Medicine, Xian'ning Medical College
Work Experience	2018.6-2019.9 Visiting Associate Professor, Translational Molecular Pathology, MD Anderson Cancer Center, USA 2017.12-present Deputy Chief Physician, Department of Pathology, Zhongnan Hospital of Wuhan University 2015.9-2015.12 Visiting Scholar, Department of Pathology, Fukushima Medical University, Japan 2014.9-2015.4 Advanced Study, Department of Pathology, Obstetrics and Gynecology Hospital of Fudan University 2010.11-present Associate Professor, Department of Pathology, Basic Medical College of Wuhan University 2002.7-2010.10 Assistant, Lecturer, Department of Pathology, Basic Medical College of Wuhan University
Awards	2022 Hubei Province Teaching Achievement Third Prize (Fifth) 2021 Excellent Mentor, Wuhan University 2020 'Challenge Cup' College Students' Innovation and Entrepreneurship Competition 2019 Hubei Province Science and Technology Progress Second Prize (Second) 2015 Hubei Province Science and Technology Progress Third Prize (Third) 2005 Zhejiang Province Science and Technology Progress Third Prize (Fourth)

University/Lab Affiliation and Title

Wuhan University

Faculty

Basic Medical Sciences

Academic Background & Achievements

2012.5-2013.8 Postdoctoral Fellow, Department of Biochemistry, Rush University Medical Center, USA
2005.9-2010.6 PhD in Internal Medicine, Renmin Hospital of Wuhan University
1999.9-2002.7 Master in Pathology and Pathophysiology, Basic Medical College of Wuhan University
1994.9-1999.7 Bachelor in Clinical Medicine, Xian'ning Medical College

Work Experience

2018.6-2019.9 Visiting Associate Professor, Translational Molecular Pathology, MD Anderson Cancer Center, USA
2017.12-present Deputy Chief Physician, Department of Pathology, Zhongnan Hospital of Wuhan University
2015.9-2015.12 Visiting Scholar, Department of Pathology, Fukushima Medical University, Japan
2014.9-2015.4 Advanced Study, Department of Pathology, Obstetrics and Gynecology Hospital of Fudan University
2010.11-present Associate Professor, Department of Pathology, Basic Medical College of Wuhan University
2002.7-2010.10 Assistant, Lecturer, Department of Pathology, Basic Medical College of Wuhan University

Awards

2022 Hubei Province Teaching Achievement Third Prize (Fifth)
2021 Excellent Mentor, Wuhan University 2020 'Challenge Cup' College Students' Innovation and Entrepreneurship Competition
2019 Hubei Province Science and Technology Progress Second Prize (Second)
2015 Hubei Province Science and Technology Progress Third Prize (Third)
2005 Zhejiang Province Science and Technology Progress Third Prize (Fourth)

Areas of Focus	Tumor energy metabolism and immune regulation Role of tumor microenvironment in energy metabolism and autophagy Tumor immune tolerance mechanisms, especially in lung cancer
Publications	Identification of a DNA-methylome-based signature for prognosis prediction in driver gene-negative lung adenocarcinoma, Shu M, Huang L, Chen Y, Wang C, Xie Z, Li S, Zhou J, Wei L, Fu T, Liu B, Chen H, Tang K, Ke Z, 2024 Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer, Liu L, Mo M, Chen X, Chao D, Zhang Y, Chen X, Wang Y, Zhang N, He N, Yuan Y, Chen H, Yang J, 2023 GOLM1 and FAM49B: potential biomarkers in HNSCC based on bioinformatics and immunohistochemical analysis, Xi Y, Zhang T, Sun W, Liang R, Ganesh S, Chen H, 2022 Different clinical significance of novel B7 family checkpoints, VISTA and HHLA2, in human lung adenocarcinoma, Long L, Zhang L, Yang Y, Zhou Y, Chen H, 2022 Recent Advancements in the mechanisms underlying resistance to PD-1/PD-L1 blockade immunotherapy, Yuan Y, Adam A, Zhao C, Chen H, 2021 High expression of PKM2 synergizes with PD-L1 in tumor cells and immune cells to predict worse survival in human lung adenocarcinoma, Long L, Chen M, Yuan Y, Ming AL, Guo W, Wu K, Chen H, 2020 Clinicopathological and prognostic significance of caveolin-1 and ATG4C expression in the epithelial ovarian cancer, Zeng Y, Chen M, Ganesh S, Hu S, Chen H, 2020 Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects, Long L, Zhao C, Ozarina M, Zhao X, Yang J, Chen H, 2019 High expression of synthesis of cytochrome c oxidase 2 and TP53-induced glycolysis and apoptosis regulator can predict poor prognosis in human lung adenocarcinoma, Liu J, Lu F, Gong Y, Zhao C, Pan Q, Ballantyne S, Zhao X, Tian S, Chen H, 2018 Role of glioma-associated GLI1 oncogene in carcinogenesis and cancer targeted therapy, Wu J, Di D, Zhao C, Liu Y, Chen H, Gong Y, Zhao X, Chen H*, 2018

Areas of Focus

Tumor energy metabolism and immune regulation
Role of tumor microenvironment in energy metabolism and autophagy
Tumor immune tolerance mechanisms, especially in lung cancer

Publications

Identification of a DNA-methylome-based signature for prognosis prediction in driver gene-negative lung adenocarcinoma, Shu M, Huang L, Chen Y, Wang C, Xie Z, Li S, Zhou J, Wei L, Fu T, Liu B, Chen H*, Tang K*, Ke Z*, 2024
Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer, Liu L, Mo M, Chen X, Chao D, Zhang Y, Chen X, Wang Y, Zhang N, He N, Yuan Y, Chen H*, Yang J*, 2023
GOLM1 and FAM49B: potential biomarkers in HNSCC based on bioinformatics and immunohistochemical analysis, Xi Y, Zhang T, Sun W, Liang R, Ganesh S, Chen H*, 2022
Different clinical significance of novel B7 family checkpoints, VISTA and HHLA2, in human lung adenocarcinoma, Long L, Zhang L, Yang Y, Zhou Y, Chen H*, 2022
Recent Advancements in the mechanisms underlying resistance to PD-1/PD-L1 blockade immunotherapy, Yuan Y, Adam A, Zhao C, Chen H*, 2021
High expression of PKM2 synergizes with PD-L1 in tumor cells and immune cells to predict worse survival in human lung adenocarcinoma, Long L, Chen M, Yuan Y, Ming AL, Guo W, Wu K*, Chen H*, 2020
Clinicopathological and prognostic significance of caveolin-1 and ATG4C expression in the epithelial ovarian cancer, Zeng Y, Chen M, Ganesh S, Hu S*, Chen H*, 2020
Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects, Long L, Zhao C, Ozarina M, Zhao X, Yang J, Chen H*, 2019
High expression of synthesis of cytochrome c oxidase 2 and TP53-induced glycolysis and apoptosis regulator can predict poor prognosis in human lung adenocarcinoma, Liu J, Lu F, Gong Y, Zhao C, Pan Q, Ballantyne S, Zhao X, Tian S, Chen H*, 2018
Role of glioma-associated GLI1 oncogene in carcinogenesis and cancer targeted therapy, Wu J, Di D, Zhao C, Liu Y, Chen H, Gong Y, Zhao X, Chen H*, 2018

Tumor Energy Metabolism Immune Regulation Microenvironment Autophagy Tolerance Lung Cancer Mechanisms

Xiaojuan Du - Peking University

Ying Zhao - Peking University

Wei Liu - Zhejiang University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us